Zivo Bioscience, Inc. 8-K

What Happened

• Zivo Bioscience, Inc. filed an 8‑K disclosing that William A. Sullivan announced his resignation as Interim Chief Financial Officer, effective March 30, 2026, and that Alison A. Cornell resigned from the Board of Directors and all board committees, effective March 26, 2026.
• The company also announced on March 27, 2026 that it intends to file a Form 15 with the SEC to suspend its reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act, effective March 30, 2026. A March 27 press release and a CEO letter to shareholders accompany the filing.

Key Details

• Resignations: William A. Sullivan (Interim CFO) effective March 30, 2026; Alison A. Cornell resigned from the Board and from the Compensation, Nominating and Audit Committees (notice given March 26, 2026).
• Reason given: Both departures are tied to the company’s cost‑cutting measures, including the decision to deregister its securities and cease public reporting; the filing states there was no disagreement with the company on matters relating to operations, policies, or practices.
• Form 15 / Reporting: Zivo intends to file Form 15 to suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act, with the suspension effective March 30, 2026.
• Communications: Press release and CEO letter dated March 27, 2026 were attached to the 8‑K.

Why It Matters

• Suspending SEC reporting (via Form 15) means Zivo will stop filing regular public reports (e.g., 10‑K, 10‑Q, current 8‑Ks), which reduces the amount of SEC‑filed financial and operational information available to investors.
• The resignations remove the interim CFO and a board member who served on key committees during a transition tied to cost cuts and deregistration; investors should note the company’s change in disclosure status and monitor company communications for replacement officers or additional governance updates.